Navigation Links
Inovio Pharmaceuticals Reports 2013 First Quarter Financial Results
Date:5/10/2013

BLUE BELL, Pa., May 10, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today reported financial results for the quarter ended March 31, 2013.

Total revenue was $1.5 million for the three months ended March 31, 2013, compared to $1.7 million for the same period in 2012. Total operating expenses were $8.1 million compared to $5.9 million. The net loss attributable to common stockholders was $8.8 million, or $0.06 per share, compared to $8.3 million, or $0.06 per share.

Revenue The decrease in revenue for the comparable periods was primarily due to timing of work performed under the company's contract with the National Institute of Allergy and Infectious Diseases (NIAID). This contract revenue amounted to $1.0 million versus $1.5 million, respectively. This NIAID contract, which provides up to $25.3 million of funding over seven years, is facilitating Inovio's development of a universal, preventive HIV DNA vaccine, PENNVAX®-GP.

Operating Expenses Research and development expenses for Q1 2013 were $5.1 million compared to $4.0 million for Q1 2012. This increase was primarily due to $788,000 in higher clinical expenses related to our ongoing HPV-003 clinical trial. General and administrative expenses were $3.0 million versus $2.5 million, respectively.

Net Loss Attributable to Common Stockholders The $590,000 increase in net loss for the comparable periods resulted primarily from an increase in operating expenses offset by a lower (non-cash) change in fair value of common stock warrants, based on a required quarterly mark to market adjustment to reflect changes in the Company's stock price.

Capital Resources As of March 31, 2013, cash and cash equivalents plus short-term investments were $28.2 million compared with $13.8 million as of December 31, 2012.

On March 7, 2013, we closed an underwritten offering of 27,377,266 shares of our common stock and warrants to purchase an agg
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
2. Inovio Pharmaceuticals to Present at Noble Financial 8th Annual Equity Conference
3. Inovios Scientific Advisory Board Chairman Elected as a Fellow by the American Association for the Advancement of Science
4. Inovio Pharmaceuticals to Present at Noble Financial Life Sciences Conference
5. Inovio Pharmaceuticals Cytomegalovirus (CMV) Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study
6. Inovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
8. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
9. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
10. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
11. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... Oral Amphotericin B program.  The company recently announced ... work involving samples from HIV/AIDS patients exposed to ... clinical studies and regulatory filings to move forward ... approximately $700,000 of funding and technological advice from ...
(Date:10/20/2014)... Oct. 20, 2014 Mapp Biopharmaceutical,s valiant ... antibody therapeutic to fight the Ebola outbreak will ... time-consuming the production of pharmaceuticals can be, according ... said that while some may be taken aback ... those with industry knowledge are well aware of ...
(Date:10/20/2014)... , Oct. 20, 2014  GenVec, Inc. (NASDAQ: ... Horovitz , Ph.D., from its board of directors effective on ... August 2003, and served as its chairman from June 2006 ... the Nominating and Corporate Governance and Audit Committees of the ... than a decade of dedicated service to GenVec, and its ...
(Date:10/19/2014)... The Latin American hardware encryption display market report ... analysis and forecast of revenue. This market was valued ... reach $2,366.8 million by 2018, at a CAGR of ... TOC of the Latin American hardware encryption market report ... It also provides a glimpse of the segmentation of ...
Breaking Biology Technology:iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Zola P. Horovitz To Retire From GenVec Board 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3
... , June 25, 2010 Industrial biotechnology ... per year through 2020. Germany ,has already established ... industry, making it an ideal site for,companies looking to ... Invest will be on hand at this year,s World ...
... German . , Organic semiconductors are very ... large area and flexible electronic components such as transistors, diodes ... A condition for success in achieving this goal is the ... in other words, to create an electronic circuit. Empa scientists ...
... ... Company) proffered his views of outsourcing product development trends as they pertain to the design ... science association in the world. , ... Irvine, CA, USA (PRWEB) June 23, 2010 -- BIT Group has ...
Cached Biology Technology:Market Demand and Innovation in Germany Propel Industrial Biotechnology Growth 2Market Demand and Innovation in Germany Propel Industrial Biotechnology Growth 3Nanowires for the electronics and optoelectronics of the future 2Nanowires for the electronics and optoelectronics of the future 3BIT Group Executive Featured in BioTechnology Series 2BIT Group Executive Featured in BioTechnology Series 3
(Date:10/15/2014)... and to an unexpected extent. The outbreak does not ... virus shows a new disease dynamic in regions, where ... the German National Academy of Sciences Leopoldina, acatech – ... Union of the German Academies of Sciences and Humanities ... , In the statement the academies call for the ...
(Date:10/14/2014)... discriminating thieves, prostate cancer tumors scavenge and hoard copper ... such avarice may be a fatal weakness. , ... kill prostate cancer cells by delivering a trove of ... diseased cells brimming with the mineral, leaving non-cancer cells ... already commercially available for other uses, could soon be ...
(Date:10/14/2014)... research team has discovered a new kind of stem cell ... that lines liver blood vessels, according to a study published ... existence of such a cell type contradicts current theory on ... may hold clues to origins of, and future treatment for, ... single cell into a complex being made up of more ...
Breaking Biology News(10 mins):Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5Prostate cancer's penchant for copper may be a fatal flaw 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 3
... change in recent decades, but species have adapted to this, ... red deer and wild boar. This has been shown ... in land use on the past, present and future distribution ... has been an increase in the area of distribution of ...
... of biomedical informatics in the Institute for Translational Sciences ... was recently honored for using advanced visual analytical methods ... along with an interdisciplinary team that included ITS director ... Ju and Sundar Victor, received a Distinguished Paper Award ...
... When you think you see a face in the clouds or ... be upside down. It turns out the answer to this ... to. Using tests of visual perception and functional magnetic resonance ... Ontario,s world-renowned Centre for Brain & Mind recently measured activity in ...
Cached Biology News:Changes in land use favor the expansion of wild ungulates 2UTMB's Bhavnani wins award for cutting-edge research in translational bioinformatics 2
Hamster serum...
... CyScribe First-Strand cDNA Labeling System - ... 50 reactions. For the generation and ... reagents are packaged together for complete ... protocols can be used for performing ...
... CyScribe First-Strand cDNA Labeling System - ... 50 reactions. For the generation and ... reagents are packaged together for complete ... protocols can be used for performing ...
... ISO 9001:2000 Certified USDA Research Registered OLAW ... Training AALAS Certified Technicians ... GLP Documentation Upon Request Focus ... for all your custom immunology service needs. ...
Biology Products: